triple negative breast cancer; (ER-, PR-, HER2-)
Jump to navigation
Jump to search
Epidemiology
- black women twice as likely as white women to be diagnosed with triple-negative breast cancer[3]
- they are also more likely to die from the disease[3]
Pathology
- TRIM37 is a driver of triple-negative breast cancer metastasis & resistance to chemotherapy
- TRIM37 point mutation variant rs57141087 is predominant in Black women & modulates TRIM37 levels through enhancer-promoter interactions
- TRIM37 overexpression in early stages of triple-negative breast cancer promotes neoplastic transformation, accelerates tumor growth & drives metastases[3]
Management
- triple negative (ER/PR receptor negative, HER2 negative) breast cancer responds to neoadjuvant chemothrapy[1]
- anthracycline-base chemotherapy for early stage triple-negative breast cancer (ER-, PR-, HER2-)[1]
- neoadjuvant chemotherapy for triple negative tumors uses standard chemotherapy (see chemotherapy for breast cancer)[1]
- atezolizumab (Tecentriq) FDA-approved for treatment of unresectable locally advanced or metastatic triple-negative breast cancer in tumors expressing PD-L1[2]
- targeting TRIM37 using nanoparticle delivery mechanisms is pending[3]
- also see breast cancer
More general terms
References
- ↑ Jump up to: 1.0 1.1 1.2 1.3 Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 18.
- ↑ Jump up to: 2.0 2.1 FDA Approval Notice. March 8, 2019 FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633065.htm
- ↑ Jump up to: 3.0 3.1 3.2 3.3 3.4 Winn S UC Davis researchers help decode the cause of aggressive breast cancer in women of color. Cancer Care. December 20, 2024 https://health.ucdavis.edu/news/headlines/uc-davis-researchers-help-decode-the-cause-of-aggressive-breast-cancer-in-women-of-color/2024/12